Member Info for doggo

The lady doth protest too much, methinks.

We are sub £5m mcap
With a mcap of £4.9 and Germany calling…

Due to receive the following in Q1/early Q2

€2.8 million first payment Leap
£250,000 loan repayment Leap
£150,000 CLN SWB (up on 16/1/23)
£600,000 2 year CLN Northern Leaf (up end Q1)
10% per annum interest with the above (£120,000)

https://cannatechtoday.com/adult-use-in-germany-will-revolutionize-cannabis-inventory-strategies/

We are sub £5m mcap

Due to receive the following in Q1/early Q2

€2.8 million first payment Leap
£250,000 loan repayment Leap
£150,000 CLN SWB (up on 16/1/23)
£600,000 2 year CLN Northern Leaf (up end Q1)
10% per annum interest with the above (£120,000)

https://www.finnewsnetwork.com.au/amp/NewsItem/394150

Tasty

Bar longlad all the folks that wanted to leave have all exited the building.
The only people willing to buy are LTH following Ed Mac’s obvious signal and are averaging down slowly and steadily trying to absorb the last of the distressed sales without putting any unwanted upward pressure on the SP.

Read

https://cannatechtoday.com/edge-of-your-seat-germanys-timetable-for-cannabis-legalization/

Unchanged much like Barwickmans undercrackers. Good for another day at least.

Same as yesterday all buys listed as sells.

So no regrets my 4x jabbed friend? Looking forward to your 5th? Lol

I’ll never have any regrets about not taking the vaccine…
I’m more focused on seed sp barwick. Let’s see what news we have over the coming sessions that can shift this beast.

Lol I’ve not posted in a week and my friend posts within 10 minutes.
Hopefully you aren’t in these figures over the coming weeks…you had your latest booster Berwick?

Other than the all-cause mortality rate in the U.K. is 30% up over the last 3 weeks compared to the 5 year average…

venescence has named Dr Richard Marshall CBE as its new CEO, effective 16 January 2023. Dr Marshall succeeds co-founder Dr Gregory Bailey, who will remain on the company’s board as Executive Chairman.

Dr Marshall brings over twenty years of business leadership to the company, with fifteen years at GSK culminating in his position as Vice President, Head of the Fibrosis & Lung Injury Discovery Performance Unit (DPU). Most recently, Dr Marshall was Senior Vice President, Global Development Head, Respiratory & Immunology of AstraZeneca. Dr Marshall was awarded a CBE in the 2021 Queen’s Honours List for his contribution to UK science and COVID-19.

Dr Richard Marshall CBE said, “I am thrilled to be joining Juvenescence at such a pivotal point in the company’s history. They are at a real inflection point, with an incredible opportunity to build on Juvenescence’s trusted brand and the Founders’ 30-year history of developing drugs to bring innovative approaches to modify and prevent the impact of aging to the market. With its broad portfolio and depth of experience, Juvenescence is building a unique ecosystem of key partnerships and acquiring the critical capabilities needed for success in this rapidly evolving field. I look forward to working with the team, our partners, and shareholders to capitalize on this incredible opportunity.”

https://twitter.com/greenhamneggs/status/1614711914831003653?s=46&t=dNCUcBtp802kUwtXggE5vg

How so chief?

I’m suggesting we get the first instalment that was due during Q1 very soon.

A ma far as the img website reads they own leap so will have had to pay for it

Read it last night barwick reads well.

Ed TR1 then Leap monies in.

Out